Market Research Life Sciences Market Research Pharmaceuticals Market Research Clinical Trial Market Research

Clinical Trial Supplies Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019–2029, Segmented By Product (Manufacturing, Supply Chain Management, Logistics, Storage & Distribution, Others); By Clinical Phase (Phase I, Phase II

Best Price Guarantee Length Publisher Published Date SKU
from $4,850 270 Pages BlueWeave Consulting February, 2023 BLWC18215475
Best Price Guarantee
Price from $4,850
Length 270 Pages
Publisher BlueWeave Consulting
Published Date February, 2023
SKU BLWC18215475

Clinical Trial Supplies Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019–2029, Segmented By Product (Manufacturing, Supply Chain Management, Logistics, Storage & Distribution, Others); By Clinical Phase (Phase I, Phase II, Phase III, Others); By Therapeutic Use (Oncology, CNS, Cardiovascular, Infectious Disease, Metabolic Disorders, Others); By End Use (Pharmaceutical, Biologics, Medical Device, Others); By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

Global Clinical Trial Supplies Market Size Booming to Touch USD 3 Billion by 2029

Global clinical trial supplies market is gaining traction because of an increasing focus on R&D innovative medicines to treat growing prevalence of various chronic and communicable illnesses as well as significant investments in clinical trials by pharmaceutical firms, governments, and research institutions.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the global clinical trial supplies market size at USD 2 billion in 2022. During the forecast period between 2023 and 2029, the global clinical trial supplies market size is projected to grow at a steady CAGR of 5.09% reaching a value of USD 2.9 billion by 2029. The increased prevalence of different chronic and communicable illnesses as well as significant investments in clinical trials by pharmaceutical firms, governments, and research institutions are key growth drivers for the global clinical trial supplies market. The global clinical trial supplies market is expected to grow during the forecast period as a result of the pharmaceutical and biotechnology firms' increasing investments in research and development activities for medication development.

Global Clinical Trial Supplies Market – Overview

Clinical trials are research projects conducted on human subjects to assess a therapeutic, surgical, or behavioral intervention. Clinical trials often fall into one of three categories: Interventional studies seek to learn more about a specific intervention or kind of treatment. Observational studies seek to understand how individuals behave in various contexts. Feasibility studies are intended to determine whether the primary research can be conducted. The provision of materials needed to execute a clinical trial is known as clinical supply or clinical trial supply. This includes the 24-hour collection and distribution of biological specimens (including infectious samples), experimental medications, kits, and other research materials and supplies, as well as knowledge and help.

Global Clinical Trial Supplies Market – By End Use

Based on end use, the global clinical trial supplies market is segmented into pharmaceuticals, biologics, medical devices, and others. Pharmaceutical companies account for the highest market share owing to the increasing number of clinical trials for drug development. Pharmaceutical companies use clinical trial supplies for collection and delivery of biological specimens, investigational drugs, and others. However, the biologics segment is expected to gain high traction during the forecast period owing to extensive research activities around the development of drugs from biologics such as blood, proteins, viruses, or living organisms.

Impact of COVID-19 on the Global Clinical Trial Supplies Market

COVID-19 elevated the critical nature of clinical trial supplies and their importance to the healthcare market. Although the global clinical trial supplies market was initially hindered during the pandemic period as the imposition of lockdowns in various countries halted the clinical trials of various therapeutic purposes, which significantly impacted the market growth. To complete vaccine development activities after the pandemic outbreak and stop any further human deaths, clinical trial sponsors, their clinical research organizations, study teams, and other important stakeholders, such as vendors, had to work cooperatively to secure clinical trial supplies.

Competitive Landscape

Major players operating in the global Clinical Trial Supplies market include Almac Group, Catalent, Inc., PCI Services, Parexel International Corporation, Sharp Packaging Services, Biocair, O&M Movianto, KLIFO A/S, Thermo Fisher Scientific, Inc., Movianto, Sharp, Catalent, Inc, Bionical Ltd., and Alium Medical Limited. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and the Global Clinical Trial Supplies Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in the Global Clinical Trial Supplies Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.


1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
2. Executive Summary
3. Global Clinical Trial Supplies Market Insights
3.1. Industry Value Chain Analysis
3.1.1. DROC Analysis
3.1.2. Growth Drivers
3.1.2.1. Increasing Pharmaceutical and Biopharmaceutical R&D Expenditures
3.1.2.2. Rising Burden of Chronic and Communicable Diseases
3.1.3. Restraints
3.1.3.1. Adverse Drug Reactions
3.1.4. Opportunities
3.1.4.1. Rising New Drug Development Trial in Emerging Countries
3.1.5. Challenges
3.1.5.1. Impact of COVID-19 on Supply Chain
3.2. Technology Advancements/Recent Developments
3.3. Regulatory Framework
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of New Entrants
3.4.4. Threat of Substitutes
3.4.5. Intensity of Rivalry
4. Global Clinical Trial Supplies Market Overview
4.1. Market Size & Forecast, 2019–2029
4.1.1. By Value (USD Million)
4.2. Market Share & Forecast
4.2.1. By Product
4.2.1.1. Manufacturing
4.2.1.2. Supply Chain Management
4.2.1.3. Logistics
4.2.1.4. Storage & Distribution
4.2.1.5. Others
4.2.2. By Clinical Phase
4.2.2.1. Phase I
4.2.2.2. Phase II
4.2.2.3. Phase III
4.2.2.4. Others
4.2.3. By Therapeutic use
4.2.3.1. Oncology
4.2.3.2. CNS
4.2.3.3. Cardiovascular
4.2.3.4. Infectious Disease
4.2.3.5. Metabolic Disorders
4.2.3.6. Others
4.2.4. By End Use
4.2.4.1. Pharmaceutical
4.2.4.2. Biologics
4.2.4.3. Medical Device
4.2.4.4. Others
4.2.5. By Region
4.2.5.1. North America
4.2.5.2. Europe
4.2.5.3. Asia Pacific (APAC)
4.2.5.4. Latin America
4.2.5.5. Middle East and Africa (MEA)
5. North America Clinical Trial Supplies Market
5.1. Market Size & Forecast, 2019–2029
5.1.1. By Value (USD Million)
5.2. Market Share & Forecast
5.2.1. By Product
5.2.2. By Clinical Phase
5.2.3. By Therapeutic use
5.2.4. By End Use
5.2.5. By Country
5.2.5.1. US
5.2.5.1.1. By Product
5.2.5.1.2. By Clinical Phase
5.2.5.1.3. By Therapeutic use
5.2.5.1.4. By End Use
5.2.5.2. Canada
5.2.5.2.1. By Product
5.2.5.2.2. By Clinical Phase
5.2.5.2.3. By Therapeutic use
5.2.5.2.4. By End Use
6. Europe Clinical Trial Supplies Market
6.1. Market Size & Forecast, 2019–2029
6.1.1. By Value (USD Million)
6.2. Market Share & Forecast
6.2.1. By Product
6.2.2. By Clinical Phase
6.2.3. By Therapeutic use
6.2.4. By End Use
6.2.5. By Country
6.2.5.1. Germany
6.2.5.1.1. By Product
6.2.5.1.2. By Clinical Phase
6.2.5.1.3. By Therapeutic use
6.2.5.1.4. By End Use
6.2.5.2. UK
6.2.5.2.1. By Product
6.2.5.2.2. By Clinical Phase
6.2.5.2.3. By Therapeutic use
6.2.5.2.4. By End Use
6.2.5.3. Italy
6.2.5.3.1. By Product
6.2.5.3.2. By Clinical Phase
6.2.5.3.3. By Therapeutic use
6.2.5.3.4. By End Use
6.2.5.4. France
6.2.5.4.1. By Product
6.2.5.4.2. By Clinical Phase
6.2.5.4.3. By Therapeutic use
6.2.5.4.4. By End Use
6.2.5.5. Spain
6.2.5.5.1. By Product
6.2.5.5.2. By Clinical Phase
6.2.5.5.3. By Therapeutic use
6.2.5.5.4. By End Use
6.2.5.6. The Netherlands
6.2.5.6.1. By Product
6.2.5.6.2. By Clinical Phase
6.2.5.6.3. By Therapeutic use
6.2.5.6.4. By End Use
6.2.5.7. Rest of Europe
6.2.5.7.1. By Product
6.2.5.7.2. By Clinical Phase
6.2.5.7.3. By Therapeutic use
6.2.5.7.4. By End Use
7. Asia-Pacific Clinical Trial Supplies Market
7.1. Market Size & Forecast, 2019–2029
7.1.1. By Value (USD Million)
7.2. Market Share & Forecast
7.2.1. By Product
7.2.2. By Clinical Phase
7.2.3. By Therapeutic use
7.2.4. By End Use
7.2.5. By Country
7.2.5.1. China
7.2.5.1.1. By Product
7.2.5.1.2. By Clinical Phase
7.2.5.1.3. By Therapeutic use
7.2.5.1.4. By End Use
7.2.5.2. India
7.2.5.2.1. By Product
7.2.5.2.2. By Clinical Phase
7.2.5.2.3. By Therapeutic use
7.2.5.2.4. By End Use
7.2.5.3. Japan
7.2.5.3.1. By Product
7.2.5.3.2. By Clinical Phase
7.2.5.3.3. By Therapeutic use
7.2.5.3.4. By End Use
7.2.5.4. South Korea
7.2.5.4.1. By Product
7.2.5.4.2. By Clinical Phase
7.2.5.4.3. By Therapeutic use
7.2.5.4.4. By End Use
7.2.5.5. Australia & New Zealand
7.2.5.5.1. By Product
7.2.5.5.2. By Clinical Phase
7.2.5.5.3. By Therapeutic use
7.2.5.5.4. By End Use
7.2.5.6. Indonesia
7.2.5.6.1. By Product
7.2.5.6.2. By Clinical Phase
7.2.5.6.3. By Therapeutic use
7.2.5.6.4. By End Use
7.2.5.7. Malaysia
7.2.5.7.1. By Product
7.2.5.7.2. By Clinical Phase
7.2.5.7.3. By Therapeutic use
7.2.5.7.4. By End Use
7.2.5.8. Singapore
7.2.5.8.1. By Product
7.2.5.8.2. By Clinical Phase
7.2.5.8.3. By Therapeutic use
7.2.5.8.4. By End Use
7.2.5.9. Philippines
7.2.5.9.1. By Product
7.2.5.9.2. By Clinical Phase
7.2.5.9.3. By Therapeutic use
7.2.5.9.4. By End Use
7.2.5.10. Vietnam
7.2.5.10.1. By Product
7.2.5.10.2. By Clinical Phase
7.2.5.10.3. By Therapeutic use
7.2.5.10.4. By End Use
7.2.5.11. Rest of APAC
7.2.5.11.1. By Product
7.2.5.11.2. By Clinical Phase
7.2.5.11.3. By Therapeutic use
7.2.5.11.4. By End Use
8. Latin America Clinical Trial Supplies Market
8.1. Market Size & Forecast, 2019–2029
8.1.1. By Value (USD Million)
8.2. Market Share & Forecast
8.2.1. By Product
8.2.2. By Clinical Phase
8.2.3. By Therapeutic use
8.2.4. By End Use
8.2.5. By Country
8.2.5.1. Brazil
8.2.5.1.1. By Product
8.2.5.1.2. By Clinical Phase
8.2.5.1.3. By Therapeutic use
8.2.5.1.4. By End Use
8.2.5.2. Mexico
8.2.5.2.1. By Product
8.2.5.2.2. By Clinical Phase
8.2.5.2.3. By Therapeutic use
8.2.5.2.4. By End Use
8.2.5.3. Argentina
8.2.5.3.1. By Product
8.2.5.3.2. By Clinical Phase
8.2.5.3.3. By Therapeutic use
8.2.5.3.4. By End Use
8.2.5.4. Peru
8.2.5.4.1. By Product
8.2.5.4.2. By Clinical Phase
8.2.5.4.3. By Therapeutic use
8.2.5.4.4. By End Use
8.2.5.5. Rest of LATAM
8.2.5.5.1. By Product
8.2.5.5.2. By Clinical Phase
8.2.5.5.3. By Therapeutic use
8.2.5.5.4. By End Use
9. Middle East & Africa Clinical Trial Supplies Market
9.1. Market Size & Forecast, 2019–2029
9.1.1. By Value (USD Million)
9.2. Market Share & Forecast
9.2.1. By Product
9.2.2. By Clinical Phase
9.2.3. By Therapeutic use
9.2.4. By End Use
9.2.5. By Country
9.2.5.1. Saudi Arabia
9.2.5.1.1. By Product
9.2.5.1.2. By Clinical Phase
9.2.5.1.3. By Therapeutic use
9.2.5.1.4. By End Use
9.2.5.2. UAE
9.2.5.2.1. By Product
9.2.5.2.2. By Clinical Phase
9.2.5.2.3. By Therapeutic use
9.2.5.2.4. By End Use
9.2.5.3. Qatar
9.2.5.3.1. By Product
9.2.5.3.2. By Clinical Phase
9.2.5.3.3. By Therapeutic use
9.2.5.3.4. By End Use
9.2.5.4. Kuwait
9.2.5.4.1. By Product
9.2.5.4.2. By Clinical Phase
9.2.5.4.3. By Therapeutic use
9.2.5.4.4. By End Use
9.2.5.5. South Africa
9.2.5.5.1. By Product
9.2.5.5.2. By Clinical Phase
9.2.5.5.3. By Therapeutic use
9.2.5.5.4. By End Use
9.2.5.6. Nigeria
9.2.5.6.1. By Product
9.2.5.6.2. By Clinical Phase
9.2.5.6.3. By Therapeutic use
9.2.5.6.4. By End Use
9.2.5.7. Algeria
9.2.5.7.1. By Product
9.2.5.7.2. By Clinical Phase
9.2.5.7.3. By Therapeutic use
9.2.5.7.4. By End Use
9.2.5.8. Rest of MEA
9.2.5.8.1. By Product
9.2.5.8.2. By Clinical Phase
9.2.5.8.3. By Therapeutic use
9.2.5.8.4. By End Use
10. Competitive Landscape
10.1. List of Key Players and Their Offerings
10.2. Global Clinical Trial Supplies Company Market Share Analysis, 2022
10.3. Competitive Benchmarking, By Operating Parameters
10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
11. Impact of Covid-19 on Global Clinical Trial Supplies Market
12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)
12.1. Alamc Group
12.2. Catalent, Inc.
12.3. PCI Services
12.4. Parexel International Corporation
12.5. Sharp Packaging Services
12.6. Biocair
12.7. O&M Movianto
12.8. KLIFO A/S
12.9. Thermo Fisher Scientific, Inc.
12.10. Movianto
12.11. Sharp
12.12. Catalent, Inc
12.13. Bionical Ltd.
12.14. Alium Medical Limited
12.15. Other Prominent Players
13. Key Strategic Recommendations
14. Research Methodology
14.1. Qualitative Research
14.1.1. Primary & Secondary Research
14.2. Quantitative Research
14.3. Market Breakdown & Data Triangulation
14.3.1. Secondary Research
14.3.2. Primary Research
14.4. Breakdown of Primary Research Respondents, By Region
14.5. Assumptions & Limitations

$4,850
$5,750
$8,150

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings